Enotria moves into CBD with OTO partnership

Imbibe

Imbibe

04 November 2019

Enotria&Coe has teamed up with CBD producer OTO to bring a range of CBD products to the on-trade.

CBD – or cannabidiol – is the non-psychoactive component found in both cannabis and hemp. The range, which includes a CBD bitters, is aimed at helping bars cater for consumers who are drinking less alcohol.

Enotria&Coe CEO Troy Christensen said: ‘While the on-trade has been battered by a plethora of challenges and the industry is under pressure to find profitable solutions for consumers shifting towards a healthier low-alcohol lifestyle, we believe that we can help bring innovative products to the trade that will help them meet these objectives.”

There are four drinks products in the OTO range: the OTO Bitters and three CBD Shots – Focus, Amplify and Balance.

‘Across the pond, the CBD industry is growing at an astounding rate – billed to be worth over $20 billion by 2024 – and OTO represents the premium, quality-driven space where we can add value to our customer’s offering,’ said Christensen. ‘This category can attract premium consumers, driving footfall and profitability to high street outlets struggling to provide experiential product innovation.’

OTO’s drinks products are now available exclusively from Enotria&Coe.

Related content

News |  Imbibe Live

OTO launches Europe's first CBD cocktail bitters

A new, non-alcoholic cocktail bitters will use the power of CBD to help drinkers relax, connect and 'amplify the moment’ in any social experience.

News |  Spirits & Cocktails

CBD brand Oto launches botanical seltzers

The no-abv canned range comes in three flavours and are all-natural, sugar-free and include a dose of CBD.

News |  Wine

Enotria acquires Coe Vintners

Wine distributor Enotria has acquired independent, family-owned wine and spirits distributor Coe Vintners, a combination that will create a formidable

News |  Mixers & More

We need to talk about CBD…

One of the most dynamic categories in the drinks trade currently – but will it live up to the hype?